MARINOMED BIOTECH AG INH.
Marinomed Biotech AG, a biopharmaceutical company, develops therapeutic products for indications in virology and immunology in Austria, other European countries, and internationally. It operates through Virology, Immunology, and Other segments. The company's products pipeline includes Budesolv for the treatment of allergic rhinitis; Tacrosolv, which is in Phase II clinical trial for inflammatory … Read more
MARINOMED BIOTECH AG INH. (93Z) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, MARINOMED BIOTECH AG INH. (93Z) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
MARINOMED BIOTECH AG INH. - Net Assets Trend (None–None)
This chart illustrates how MARINOMED BIOTECH AG INH.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for MARINOMED BIOTECH AG INH. (None–None)
The table below shows the annual net assets of MARINOMED BIOTECH AG INH. from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to MARINOMED BIOTECH AG INH.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
MARINOMED BIOTECH AG INH. Competitors by Market Cap
The table below lists competitors of MARINOMED BIOTECH AG INH. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Formetal Co. Ltd
KQ:119500
|
$21.48 Million |
|
RDE, Inc. Common Stock
NASDAQ:RSTN
|
$21.48 Million |
|
Neo-Neon Holdings Limited
TW:911868
|
$21.49 Million |
|
Eskay Mining Corp
PINK:ESKYF
|
$21.49 Million |
|
Simple Mart Retail Co Ltd
TW:2945
|
$21.47 Million |
|
CMR S.A.B. de C.V
MX:CMRB
|
$21.46 Million |
|
SIMEC Atlantis Energy Limited
PINK:SMAYF
|
$21.46 Million |
|
Buda Juice, Inc.
NYSE MKT:BUDA
|
$21.46 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MARINOMED BIOTECH AG INH.'s equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares MARINOMED BIOTECH AG INH.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently MARINOMED BIOTECH AG INH. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares MARINOMED BIOTECH AG INH.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MARINOMED BIOTECH AG INH. (93Z) | €- | N/A | N/A | $21.48 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |